74 results on '"Biasco, Guido"'
Search Results
2. The National Tumor Association Foundation (ANT): A 30 year old model of home palliative care.
- Author
-
Casadio, Marina, Biasco, Guido, Abernethy, Amy, Bonazzi, Valeria, Pannuti, Raffaella, and Pannuti, Franco
- Subjects
- *
CANCER patients , *PALLIATIVE treatment , *CAREGIVERS , *HOSPICE care , *NURSING care facilities - Abstract
Background: Models of palliative care delivery develop within a social, cultural, and political context. This paper describes the 30-year history of the National Tumor Association (ANT), a palliative care organization founded in the Italian province of Bologna, focusing on this model of home care for palliative cancer patients and on its evaluation. Methods: Data were collected from the 1986-2008 ANT archives and documents from the Emilia-Romagna Region Health Department, Italy. Outcomes of interest were changed in: number of patients served, performance status at admission (Karnofsky Performance Status score [KPS]), length of participation in the program (days of care provided), place of death (home vs. hospital/hospice), and satisfaction with care. Statistical methods included linear and quadratic regressions. A linear and a quadratic regressions were generated; the independent variable was the year, while the dependent one was the number of patients from 1986 to 2008. Two linear regressions were generated for patients died at home and in the hospital, respectively. For each regression, the R square, the unstandardized and standardized coefficients and related P-values were estimated. Results: The number of patients served by ANT has increased continuously from 131 (1986) to a cumulative total of 69,336 patients (2008), at a steady rate of approximately 121 additional patients per year and with no significant gender difference. The annual number of home visits increased from 6,357 (1985) to 904,782 (2008). More ANT patients died at home than in hospice or hospital; this proportion increased from 60% (1987) to 80% (2007). The rate of growth in the number of patients dying in hospital/hospice was approximately 40 patients/year (p < 0.01), vs. approximately 177 patients/year for patients who died at home. The percentage of patients with KPS < 40 at admission decreased from 70% (2003) to 30% (2008); the percentage of patients with KPS > 40 increased. Mean days of care for patients with KPS > 40 exceeded mean days for patients with KPS < 40 (p < 0.001). Patients and caregivers reported high satisfaction with care in each year of assessment; in 2008, among 187 interviewed caregivers, 95% judged the quality of doctors' assistance, and 91% judged the quality of nurses' assistance, to be "optimal." Conclusions: The ANT home care model of palliative care delivery has been well-received, with progressively growing numbers of patients served. It has resulted in a greater proportion of home deaths and in patients' accessing palliative care at an earlier point in the disease trajectory. Changes in ANT chronicle palliative care trends in general. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
3. Virtual Reality for advanced cancer patients assisted at home: A randomized controlled interventional study.
- Author
-
Giannelli, Andrea, Moscato, Serena, Ostan, Rita, Pannuti, Raffaella, Chiari, Lorenzo, Biasco, Guido, and Varani, Silvia
- Subjects
- *
CLINICAL trials , *CANCER patients , *VIRTUAL reality , *PSYCHOTHERAPY , *BRIEF Pain Inventory , *WORRY - Abstract
Objective: Virtual Reality (VR) has been demonstrated to be an effective option for integrating psychological interventions in different therapeutic settings. This randomized controlled interventional study aims to assess the effects of VR, compared to tablet controlled intervention, on anxiety, depression, pain, and short‐term psychophysical symptoms in advanced cancer patients assisted at home. Methods: Participants were provided with a VR headset or a tablet (TAB) for 4 days. On the first and last day, anxiety and depression were measured by Hospital Anxiety and Depression Scale and pain by Brief Pain Inventory. Before and after each VR and tablet session, symptoms were collected by the Edmonton Symptom Assessment Scale (ESAS). Results: Fifty‐three patients (27 VR vs. 26 TAB) completed the study. Anxiety significantly decreased in the VR group after the 4‐day intervention. The analysis of ESAS showed a significant improvement in pain (p = 0.013), tiredness (p < 0.001), and anxiety (p = 0.013) for TAB group, and a significant reduction in tiredness (p < 0.001) in the VR group. Conclusions: Technological and user‐friendly tools, such as VR and tablets, might be integrated with traditional psychological interventions to improve anxiety and cancer‐related short‐term symptoms. Further studies are needed to better consolidate the possible beneficial effects of VR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours.
- Author
-
Nannini, Margherita, Biasco, Guido, and Pantaleo, Maria A
- Subjects
- *
BIOMARKERS , *GASTROINTESTINAL stromal tumors - Abstract
A letter to the editor "An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild type gastrointestinal stromal tumours" by N.A. Wong and others which appeared in the 2015 issue of the periodical is presented.
- Published
- 2015
- Full Text
- View/download PDF
5. Delirium Rates in Advanced Cancer Patients Admitted to Different Palliative Care Settings: Does It Make the Difference?
- Author
-
Pallotti, Maria Caterina, López-Fidalgo, Jesús, Biasco, Guido, Celin, Daniela, Centeno, Carlos, Paragona, Marco, Moroni, Matteo, and Noguera, Antonio
- Subjects
- *
DIAGNOSIS of delirium , *CANCER patients , *CHI-squared test , *COMPARATIVE studies , *HOSPICE care , *HOSPITAL admission & discharge , *LONGITUDINAL method , *SCIENTIFIC observation , *PALLIATIVE treatment , *PATIENTS , *TUMOR classification , *DESCRIPTIVE statistics - Abstract
Background: Delirium in advanced cancer inpatient ranges between 13% and 85%. Reasons for this variability on the reported data could be related to the setting where they are admitted. Methods: This is an observational, comparative, prospective study on delirium diagnosis and delirium course of advanced cancer inpatients in two different palliative care settings. Hospice (C1) versus palliative care supportive team (C2). Differences between delirium precipitants, delirium treatment, and delirium survival were observed. Results: From 582 consecutive admissions, 494 from C1 and 88 from C2, finally 227 patients met inclusion criteria, were entered in the study. Total population delirium rate at admission, if we add both centers, was 57 patients (25%), 46 (26%) from C1 and 11 (22%) from C2; no statistically significant differences between delirium rate at admission between the two centers were found (χ2). When delirium course between delirious patients admitted in C1 and C2 was analyzed, a significantly higher rate of delirium reversibility was found in C2 [11/14 (78%)] versus [9/65 (14%)] in C1 (χ2p ≤ 0.001). Conclusion: The frequency of delirium at admission and during the hospitalization in advanced cancer patients does not seem to be related to the setting, what seems to be related is the delirium course. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Spontaneous Regression of a Desmoid Intraabdominal Tumor in a Patient Affected by Familial Adenomatous Polyposis.
- Author
-
Biasco, Guido, Pantaleo, Maria Abbondanza, Nobili, Elisabetta, and Monti, Carlo
- Subjects
- *
TUMORS , *DIGESTIVE system diseases , *LETTERS to the editor - Abstract
Presents a letter to the editor about spontaneous regression of a desmoid intraabdominal tumor in a patient affected by familial adenomatous polyposis, published in the 2004 issue of the "American Journal of Gastroenterology."
- Published
- 2004
- Full Text
- View/download PDF
7. Treatment of brain metastases of malignant melanoma with temozolomide.
- Author
-
Biasco, Guido, Pantaleo, Maria A., Casadei, Simona, Biasco, G, Pantaleo, M A, and Casadei, S
- Subjects
- *
LETTERS to the editor , *BRAIN cancer , *ANTINEOPLASTIC agents , *MELANOMA diagnosis , *BRAIN tumors , *LUNG tumors , *MAGNETIC resonance imaging , *MELANOMA , *SKIN tumors , *DACARBAZINE , *THERAPEUTICS ,BRAIN tumor diagnosis - Abstract
A letter to the editor about the treatment of brain metastases of melanoma with temozolomide is presented.
- Published
- 2001
- Full Text
- View/download PDF
8. Distance Monitoring of Advanced Cancer Patients with Impaired Cardiac and Respiratory Function Assisted at Home: A Study Protocol in Italy.
- Author
-
Ostan, Rita, Varani, Silvia, Giannelli, Andrea, Malavasi, Italo, Pannuti, Francesco, Pannuti, Raffaella, Biasco, Guido, and Mattioli, Anna Vittoria
- Subjects
- *
CANCER patients , *CAREGIVERS , *SCIENTIFIC knowledge , *CARDIAC patients , *CONTINUUM of care , *CANCER patient care , *VITAL statistics , *COMMUNICATIVE disorders - Abstract
During the pandemic, telemedicine and telehealth interventions have been leading in maintaining the continuity of care independently of patients' physical location. However, the evidence available about the effectiveness of the telehealth approach for advanced cancer patients with chronic disease is limited. This interventional randomized pilot study aims to evaluate the acceptability of a daily telemonitoring of five vital parameters (heart rate, respiratory rate, blood oxygenation, blood pressure, and body temperature) using a medical device in advanced cancer patients with relevant cardiovascular and respiratory comorbidities assisted at home. The purpose of the current paper is to describe the design of the telemonitoring intervention in a home palliative and supportive care setting with the objective of optimizing the management of patients, improving both their quality of life and psychological status and the caregiver's perceived care burden. This study may improve scientific knowledge regarding the impact of telemonitoring. Moreover, this intervention could foster continuous healthcare delivery and closer communication among the physician, patient and family, enabling the physician to have an updated overview of the clinical trajectory of the disease. Finally, the study may help family caregivers to maintain their habits and professional position and to limit financial consequences. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Re: Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations.
- Author
-
Brandi, Giovanni, Biasco, Guido, and Tavolari, Simona
- Subjects
- *
LETTERS to the editor , *PHARMACODYNAMICS , *SIMVASTATIN - Abstract
A letter to the editor is presented in response to a study titled "Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer with KRAS Mutations," by J. Lee, I. Lee , B. Han, et al. published online on March 11, 2011.
- Published
- 2011
- Full Text
- View/download PDF
10. Progress in Genomic Technology: A New Challenge for the Palliative Medicine?
- Author
-
Astolfi, Annalisa, Biasco, Guido, Bruera, Eduardo, and Surbone, Antonella
- Published
- 2010
- Full Text
- View/download PDF
11. c-Met as a Target for Personalized Therapy.
- Author
-
Garajová, Ingrid, Giovannetti, Elisa, Biasco, Guido, and Peters, Godefridus J.
- Subjects
- *
PROTO-oncogenes , *ONCOLOGY , *MITOGEN-activated protein kinases , *CELL membranes , *CELL proliferation , *MANAGEMENT - Abstract
MET and its ligand HGF are involved in many biological processes, both physiological and pathological, making this signaling pathway an attractive therapeutic target in oncology. Downstream signaling effects are transmitted via mitogen-activated protein kinase (MAPK), PI3K (phosphoinositide 3-kinase protein kinase B)/AKT, signal transducer and activator of transcription proteins (STAT), and nuclear factor-κB. The final output of the terminal effector components of these pathways is activation of cytoplasmic and nuclear processes leading to increases in cell proliferation, survival, mobilization and invasive capacity. In addition to its role as an oncogenic driver, increasing evidence implicates MET as a common mechanism of resistance to targeted therapies including EGFR and VEGFR inhibitors. In the present review, we summarize the current knowledge on the role of the HGF-MET signaling pathway in cancer and its therapeutic targeting (HGF activation inhibitors, HGF inhibitors, MET antagonists and selective/nonselective MET kinase inhibitors). Recent advances in understanding the role of this pathway in the resistance to current anticancer strategies used in lung, kidney and pancreatic cancer are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Effect of Eradication of Helicobacter pylori in Patients with Fundic Atrophic Gastritis.
- Author
-
Tucci, Antonio, Biasco, Guido, and Paparo, Giovanni Francesco
- Subjects
- *
LETTERS to the editor , *HELICOBACTER pylori - Abstract
This article presents a letter regarding the possible role helicobacter pylori plays in the pathology of nonautoimmune atrophic gastritis of the fundus.
- Published
- 1997
- Full Text
- View/download PDF
13. Comparative Analysis of Specialization in Palliative Medicine Processes Within the World Health Organization European Region.
- Author
-
Centeno, Carlos, Bolognesi, Deborah, and Biasco, Guido
- Subjects
- *
PALLIATIVE treatment , *EUROPEANS , *CANCER patients , *ONCOLOGY research , *COMPARATIVE studies , *DISEASES - Abstract
Context Palliative medicine (PM), still in the development phase, is a new, growing specialty aimed at caring for both oncology and non-oncology patients. There is still confusion about the training offered in the various European PM certification programs. Objectives To provide a detailed, comparative update and analysis of the PM certification process in Europe, including the different training approaches and their main features. Methods Experts from each country completed an online survey addressing historical background, program name, training requirements, length of time in training, characteristic and content, official certifying institution, effectiveness of accreditation, and 2013 workforce capacity. We prepared a comparative analysis of the data provided. Results In 2014, 18 of 53 European countries had official programs on specialization in PM (POSPM): Czech Republic, Denmark, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Italy, Latvia, Malta, Norway, Poland, Portugal, Romania, Slovakia, and the U.K. Ten of these programs were begun in the last five years. The PM is recognized as a “specialty,” “subspecialty,” or “special area of competence,” with no substantial differences between the last two designations. The certification contains the term “palliative medicine” in most countries. Clinical training varies, with one to two years being the most frequent duration. There is a clear trend toward establishing the POSPM as a mandatory condition for obtaining a clinical PM position in countries' respective health systems. Conclusion PM is growing as a specialization field in Europe. Processes leading to certification are generally long and require substantial clinical training. The POSPM education plans are heterogeneous. The European Association for Palliative Care should commit to establishing common learning standards, leading to additional European-based recognition of expertise in PM. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Tackling the Pandemic a Year Later: Burnout Among Home Palliative Care Clinicians.
- Author
-
Ercolani, Giacomo, Varani, Silvia, Ostan, Rita, Franchini, Luca, Yaaqovy, Ahikam David, Pannuti, Raffaella, Biasco, Guido, and Bruera, Eduardo
- Subjects
- *
MASLACH Burnout Inventory , *PALLIATIVE treatment , *PSYCHOLOGICAL burnout , *MEDICAL personnel , *GENERAL Health Questionnaire - Abstract
Context: The COVID-19 pandemic strongly challenged healthcare workers, disrupting their work routine and impacting on their professional life. A previous investigation explored levels of burnout and psychological morbidity among palliative care professionals (PCPs) during COVID-19 first wave.Objective: To update data about burnout and psychological morbidity among PCPs after a year of COVID-19 pandemic.Methods: The same questionnaires on burnout (Maslach Burnout Inventory, MBI) and psychological morbidity (General Health Questionnaire 12 items, GHQ-12) were administered a year after. Differences in MBI and GHQ-12 scores obtained in the two studies (COVID2020 and COVID2021), as well as distributions of PCPs showing burnout symptoms and psychological morbidity were analyzed and compared. We also explored the association between the three dimensions of burnout and socio-demographic and professional characteristics.Results: The sample consisted of 145 PCPs (59% physicians and 41% nurses). Response rate (70.4%) was quite similar to the previous study (73.2%). No differences were observed in the frequency of burnout between COVID2021 and COVID2020; the PCPs in COVID2021 reported marginally higher level of EE (P = .049) and this result is confirmed in physicians (P = .010) while no difference was observed in nurses (P = .326). In addition, the percentage of cases showing psychological morbidity significantly decreased.Conclusion: Our findings show stable levels of burnout and decreasing levels of psychological morbidity among PCPs one year after the onset of the COVID-19 pandemic. However, more research is needed to detail the significance of emotional exhaustion dimension, a variable influenced by the survey. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
15. An online international comparison of palliative care identification in primary care using the Surprise Question.
- Author
-
White, Nicola, Oostendorp, Linda JM, Vickerstaff, Victoria, Gerlach, Christina, Engels, Yvonne, Maessen, Maud, Tomlinson, Christopher, Wens, Johan, Leysen, Bert, Biasco, Guido, Zambrano, Sofia, Eychmüller, Steffen, Avgerinou, Christina, Chattat, Rabih, Ottoboni, Giovanni, Veldhoven, Carel, and Stone, Patrick
- Subjects
- *
SURVIVAL , *STATISTICS , *LIFE expectancy , *CROSS-sectional method , *MULTIVARIATE analysis , *PHYSICIANS' attitudes , *REGRESSION analysis , *PRIMARY health care , *COMPARATIVE studies , *CASE studies , *PALLIATIVE treatment - Abstract
Background: The Surprise Question ('Would I be surprised if this patient died within 12 months?') identifies patients in the last year of life. It is unclear if 'surprised' means the same for each clinician, and whether their responses are internally consistent. Aim: To determine the consistency with which the Surprise Question is used. Design: A cross-sectional online study of participants located in Belgium, Germany, Italy, The Netherlands, Switzerland and UK. Participants completed 20 hypothetical patient summaries ('vignettes'). Primary outcome measure: continuous estimate of probability of death within 12 months (0% [certain survival]–100% [certain death]). A threshold (probability estimate above which Surprise Question responses were consistently 'no') and an inconsistency range (range of probability estimates where respondents vacillated between responses) were calculated. Univariable and multivariable linear regression explored differences in consistency. Trial registration: NCT03697213. Setting/participants: Registered General Practitioners (GPs). Of the 307 GPs who started the study, 250 completed 15 or more vignettes. Results: Participants had a consistency threshold of 49.8% (SD 22.7) and inconsistency range of 17% (SD 22.4). Italy had a significantly higher threshold than other countries (p = 0.002). There was also a difference in threshold levels depending on age of clinician, for every yearly increase, participants had a higher threshold. There was no difference in inconsistency between countries (p = 0.53). Conclusions: There is variation between clinicians regarding the use of the Surprise Question. Over half of GPs were not internally consistent in their responses to the Surprise Question. Future research with standardised terms and real patients is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Genetic Factors Associated With Pain Severity, Daily Opioid Dose Requirement, and Pain Response Among Advanced Cancer Patients Receiving Supportive Care.
- Author
-
Yennurajalingam, Sriram, Astolfi, Annalisa, Indio, Valentina, Beccaro, Monica, Schipani, Angela, Yu, Robert, Shete, Sanjay, Reyes-Gibby, Cielito, Lu, Zhanni, Williams, Janet L., Yeun, Sai-Ching, Anderson, Aimee E., Biasco, Guido, and Bruera, Eduardo
- Subjects
- *
DRUG dosage , *PAIN medicine , *ONCOLOGY , *CANCER patient care , *GENETIC testing , *PAIN management , *CANCER patients , *STAT proteins , *PHENOTYPES , *THERAPEUTIC use of narcotics , *RESEARCH , *PAIN , *ANALGESICS , *RESEARCH methodology , *GENETIC polymorphisms , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *TUMORS , *LONGITUDINAL method , *DISEASE complications - Abstract
Background: Current understanding of genetic factors associated with pain severity, and improvement of pain with opioids in advanced cancer patients (AC) is inadequate for delivery of personalized pain therapy (PPT). Therefore, the aim of this study was to determine the genetic factors associated with pain severity, daily opioid dose, and pain response in AC patients receiving supportive care.Methods: In this prospective study, AC patients were eligible if they had cancer pain ≥4/10 on Edmonton Symptom Assessment Scale (ESAS) - Pain Item and needed opioid rotation for pain control by specialist at the outpatient supportive care center. Association of genetic factors with pain phenotype was assessed using logistic regression models and SKATO (Gene-block) analysis.Results: About 174/178 (98%) patient samples were analyzed. After adjustment for demographic and clinical variables, pain severity was negatively associated with intron variant alleles in OPRM1 rs9322446, P = 0.02; rs2270459, P = 0.038; rs62052210, P = 0.038. Opioid daily dose was positively associated NFKBIA rs2233419, P = 0.008; rs2233417, P = 0.007; rs3138054, P = 0.008; rs1050851, P = 0.015; ORPM1 rs9479759, P = 0.046; rs2003185, P = 0.047; rs636433, P = 0.044; COMT (rs9306234, P = 0.014; rs165728, P = 0.014; rs2020917, P = 0.036; rs165728, P = 0.034); ARRB2 (rs1045280, P = 0.045); and pain response to opioids was negatively associated OPRM1 rs1319339, P = 0.024; rs34427887, P = 0.048; and COMT rs4646316, P = 0.03; rs35478083, P = 0.028, respectively. SKATO analysis showed association between pain severity and CXCL8 (P = 0.0056), and STAT6 (P = 0.0297) genes respectively, and pain response with IL-6 (P = 0.00499).Conclusions: This study identified that SNPs of OPRM1, COMT, NFKBIA, CXCL8, IL-6, STAT6, and ARRB2 genes were associated with pain severity, opioid daily dose, and pain response in AC receiving supportive care. Additional studies are needed to validate our findings for PPT. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. Does Delirium Phenomenology in Persons with Advanced Cancer Follow a Specific Pattern?
- Author
-
Pallotti, Maria Caterina, Lopez-Fidalgo, Jesus, Centeno, Carlos, Celin, Daniela, Biasco, Guido, Giovannini, Maddalena, Maltoni, Marco, and Noguera, Antonio
- Subjects
- *
CANCER patient psychology , *COGNITION disorders , *SCIENTIFIC observation , *PHENOMENOLOGY , *COMPARATIVE studies , *NEUROLOGIC manifestations of general diseases , *DELIRIUM , *QUALITY of life , *SHORT-term memory , *LONGITUDINAL method - Abstract
Objective: Recognizing delirium phenomenology (DP) aids the early diagnosis of this syndrome and improves quality of life in patients with advanced cancer. The aim of this study was to identify the neurobehavioral and cognitive patterns of delirium-related symptoms in persons with advanced cancer. Methods: We conducted an observational comparative prospective study on delirium in patients with advanced cancer in different palliative care settings, assessing the presentation/evolution of DP with the Memorial delirium assessment scale (MDAS). Results: Two hundred twenty-seven patients were enrolled on hospital/hospice admission. Of these, 57 were admitted with delirium, 170 without delirium, and 31 developed delirium during hospitalization. Of the 88 patients admitted with delirium or who developed it during hospitalization, only 32 underwent two consecutive MDAS evaluations (at diagnosis and after one week). Delirium resolved in 22 patients (first average MDAS score 10.08 vs. second 3.6 [p < 0.001]). Disorientation, short-term memory, and memory span were altered in all patients with unresolved delirium. The same features were altered in 18 (80%), 17 (80%), and 16 (70%) of the patients with resolved delirium, respectively, and in 58 (35%), 114 (67%), and 38 (23%) of no-delirium patients, respectively. Conclusion: Cognitive-related symptoms appear to be the most prevalent and earliest signs of DP in patients with advanced cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Home palliative care professionals perception of challenges during the Covid-19 outbreak: A qualitative study.
- Author
-
Franchini, Luca, Varani, Silvia, Ostan, Rita, Bocchi, Ilenia, Pannuti, Raffaella, Biasco, Guido, and Bruera, Eduardo
- Subjects
- *
OCCUPATIONAL roles , *PROFESSIONAL practice , *NONPROFIT organizations , *HOME care services , *ATTITUDE (Psychology) , *RESEARCH methodology , *MEDICAL personnel , *INTERVIEWING , *FAMILIES , *QUALITATIVE research , *RESPONSIBILITY , *PSYCHOSOCIAL factors , *COMMUNICATION , *THEMATIC analysis , *PATIENT education , *PALLIATIVE treatment , *COVID-19 pandemic , *CANCER patient medical care - Abstract
Background: Home palliative care services have played an essential role during the first wave of the SARS-CoV-2 outbreak by providing symptom control, drug procurement, and psychological support for frail patients and their families unable to leave their homes. Aim: To understand how home palliative care professionals were affected by the outbreak, describing changes and challenges in their daily work as well as their reactions to the Covid-19 pandemic in Italy. Design: Qualitative study conducted using telephone semi-structured interviews, with thematic analysis. Setting/participants: Thirty home care professionals working for an Italian non-profit organization which provides home palliative care for cancer patients and their families. Results: Three main themes were identified. The first theme showed both patient-related and practice-related challenges participants faced in their daily work, requiring the implementation of different communication methods and patient and family education on risk prevention. The second theme showed the perception of increased responsibility and being the only landmark for family played a decisive role in participants' positive attitude. The third theme highlighted the participants' perception of the critical role of a home care setting in this emergency situation. Conclusions: The first wave of the Covid-19 pandemic brought many challenges and stressors for home palliative care professionals. On the other side, they reported a satisfaction with their critical role in carrying out their work with patients at risk. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Caring Advanced Cancer Patients at Home During COVID-19 Outbreak: Burnout and Psychological Morbidity Among Palliative Care Professionals in Italy.
- Author
-
Varani, Silvia, Ostan, Rita, Franchini, Luca, Ercolani, Giacomo, Pannuti, Raffaella, Biasco, Guido, and Bruera, Eduardo
- Subjects
- *
COVID-19 pandemic , *PSYCHOLOGICAL burnout , *CANCER patient care , *PALLIATIVE treatment , *MASLACH Burnout Inventory , *COVID-19 - Abstract
Context: Providing palliative care (PC) at home for patients with advanced cancer has become essential during the COVID-19 emergency. Nevertheless, the home PC professionals (PCPs) faced a challenging situation because of increased number of discharged patients, reduced availability of health-care facilities, and physical/relational barriers between them and patients.Objectives: This study aimed to investigate the impact of COVID-19 pandemic on burnout and psychological morbidity among home PCPs in Italy.Methods: One hundred and ninety-eight PC physicians and nurses working in home assistance in Italy were invited to participate. The results obtained by the investigation conducted during the COVID-19 emergency (COVID2020) were compared with data collected in 2016 in the same setting (BURNOUT2016). The questionnaires (socio-demographics, Maslach Burnout Inventory and General Health Questionnaire-12) were the same for both the surveys. The PCPs participating in COVID2020 survey (n = 145) were mostly the same (70%) who participated in the BURNOUT2016 study (n = 179).Results: One hundred and forty-five PCPs participated in the study (response rate 73.2%). During the COVID-19 emergency, home PCPs presented a lower burnout frequency (P < .001) and higher level of personal accomplishment than in 2016 (P = .047). Conversely, the risk for psychological morbidity was significantly higher during the pandemic (P < .001).Conclusions: In the age of COVID-19, the awareness of being at the forefront of containing the pandemic along with the sense of responsibility toward their high-risk patients may arouse PCPs' psychological distress, but, on the other hand, this condition may improve their sense of professional satisfaction and personal accomplishment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
20. How Do Experienced Professors Teach Palliative Medicine in European Universities? A Cross-Case Analysis of Eight Undergraduate Educational Programs.
- Author
-
Noguera, Antonio, Bolognesi, Deborah, Garralda, Eduardo, Beccaro, Monica, Kotlinska-Lemieszek, Aleksandra, Furst, Carl Johan, Ellershaw, John, Elsner, Frank, Csikos, Agnes, Filbet, Marilene, Biasco, Guido, and Centeno, Carlos
- Subjects
- *
EVALUATION of medical education , *CURRICULUM planning , *DISCUSSION , *INTERVIEWING , *LECTURE method in teaching , *RESEARCH methodology , *MEDICAL students , *MEDICAL research , *PALLIATIVE treatment , *REFLECTION (Philosophy) , *ROLE playing , *UNIVERSITIES & colleges , *ADULT education workshops , *CLINICAL competence , *EMPLOYMENT portfolios , *TEACHING methods , *UNDERGRADUATES , *COLLEGE teacher attitudes , *EDUCATION - Abstract
Background: In Europe in recent decades, university teaching of palliative medicine (PM) has evolved. In some countries it has been introduced as a compulsory subject in all medical schools, but in a majority of countries it remains an isolated subject at few universities. Objective: To explore how PM has been introduced into the curricula and how it is currently being taught at different European universities. Method: Case study method using face-to-face semistructured interviews with experienced PM professors, comparing how they have developed PM undergraduate programs at their universities. Results: An intentional sample of eight university professors from Spain, France, UK, Italy, Hungary, Sweden, Germany, and Poland was chosen. The introduction of PM in the universities depends on the existence of a favorable social and political context in relation to palliative care and the initiative of pioneers, trusted by students, to push this education forward. A PM curriculum frequently starts as an optional subject and becomes mandatory in a short period. In the reported universities, PM uses a wide variety of teaching methods, such as lectures, workshops, role-plays, and discussions. PM assessment included tests, discussions, reflections, portfolios, and research works. According to respondents' opinions, lack of recognition, funding, and accredited teachers, along with competition from other curricula, are the main barriers for palliative medicine teaching development at universities. Conclusion: Diverse paths and tools have been identified for PM teaching in Europe. The described cases may shed light on other medical schools to develop PM curricula. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma.
- Author
-
Urbini, Milena, Nannini, Margherita, Astolfi, Annalisa, Indio, Valentina, Vicennati, Valentina, De Luca, Matilde, Tarantino, Giuseppe, Corso, Federica, Saponara, Maristella, Gatto, Lidia, Santini, Donatella, Di Dalmazi, Guido, Pagotto, Uberto, Pasquali, Renato, Pession, Andrea, Biasco, Guido, and Pantaleo, Maria A.
- Subjects
- *
PHEOCHROMOCYTOMA , *CANCER genes , *EXOMES , *DISEASE susceptibility , *HERITABILITY , *SOMATIC mutation - Abstract
Background. Pheochromocytomas (PCCs) show the highest degree of heritability in human neoplasms. However, despite the wide number of alterations until now reported in PCCs, it is likely that other susceptibility genes remain still unknown, especially for those PCCs not clearly syndromic. Methods. Whole exome sequencing of tumor DNA was performed on a set of twelve PCCs clinically defined as sporadic. Results. About 50% of PCCs examined had somatic mutations on the known susceptibility VHL, NF1, and RET genes. In addition to these driver events, mutations on SYNE1, ABCC10, and RAD54B genes were also detected. Moreover, extremely rare germline variants were present in half of the sporadic PCC samples analyzed, in particular variants of MAX and SAMD9L were detected in the germline of cases wild-type for mutations in the known susceptibility genes. Conclusions. Additional somatic passenger mutations can be associated with known susceptibility VHL, NF1, and RET genes in PCCs, and a wide number of germline variants with still unknown clinical significance can be detected in these patients. Therefore, many efforts should be aimed to better define the pathogenetic role of all these germline variants for discovering novel potential therapeutic targets for this disease still orphan of effective treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
- Author
-
Indio, Valentina, Astolfi, Annalisa, Tarantino, Giuseppe, Urbini, Milena, Patterson, Janice, Nannini, Margherita, Saponara, Maristella, Gatto, Lidia, Santini, Donatella, do Valle, Italo F., Castellani, Gastone, Remondini, Daniel, Fiorentino, Michelangelo, von Mehren, Margaret, Brandi, Giovanni, Biasco, Guido, Heinrich, Michael C., and Pantaleo, Maria Abbondanza
- Subjects
- *
GASTROINTESTINAL stromal tumors , *GENETIC mutation , *PLATELET-derived growth factor , *MUTANT proteins , *CELL cycle - Abstract
Gastrointestinal stromal tumors (GIST) carrying the D842V activating mutation in the platelet-derived growth factor receptor alpha (PDGFRA) gene are a very rare subgroup of GIST (about 10%) known to be resistant to conventional tyrosine kinase inhibitors (TKIs) and to show an indolent behavior. In this study, we performed an integrated molecular characterization of D842V mutant GIST by whole-transcriptome and whole-exome sequencing coupled with protein-ligand interaction modelling to identify the molecular signature and any additional recurrent genomic event related to their clinical course. We found a very specific gene expression profile of D842V mutant tumors showing the activation of G-protein-coupled receptor (GPCR) signaling and a relative downregulation of cell cycle processes. Beyond D842V, no recurrently mutated genes were found in our cohort. Nevertheless, many private, clinically relevant alterations were found in each tumor (TP53, IDH1, FBXW7, SDH-complex). Molecular modeling of PDGFRA D842V suggests that the mutant protein binds imatinib with lower affinity with respect to wild-type structure, showing higher stability during the interaction with other type I TKIs (like crenolanib). D842V mutant GIST do not show any actionable recurrent molecular events of therapeutic significance, therefore this study supports the rationale of novel TKIs development that are currently being evaluated in clinical studies for the treatment of D842V mutant GIST. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
- Author
-
Brandi, Giovanni, Paragona, Marco, Campana, Davide, Brighi, Nicole, Bondi, Arrigo, Pantaleo, Maria Abbondanza, Corbelli, Jody, Barbera, Maria Aurelia, and Biasco, Guido
- Published
- 2018
- Full Text
- View/download PDF
24. Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients.
- Author
-
Frega, Giorgio, Garajová, Ingrid, Palloni, Andrea, Barbera, Maria Aurelia, Trossello Pastore, Marco, Faccioli, Luca, Spinardi, Luca, De Lorenzo, Stefania, Cubelli, Marta, Pantaleo, Maria Abbondanza, Biasco, Guido, and Brandi, Giovanni
- Subjects
- *
BONE metastasis , *BRAIN tumors , *METASTASIS , *SURVIVAL analysis (Biometry) , *DISEASE incidence , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *DISEASE complications ,BILE duct tumors - Abstract
Objective: Brain metastases (BMs) from biliary tract cancer (BTC) are extremely rare. The aim of our study was to report the incidence of BMs in patients with BTC. Methods: We retrospectively analyzed a series of 450 patients with BTC. Presence of brain lesions was investigated only when symptoms were evident. Cumulative incidence, median overall survival (OS) from detection of BMs, median OS from cancer diagnosis, and median time from cancer diagnosis to detection of BMs were evaluated. Results: In our series, 6 patients developed BMs with an incidence of about 1.4%. Median OS from detection of BMs and from cancer diagnosis was, respectively, 3.7 (0.9-17.8) and 23 (9.9-57.6) months. Median time between cancer diagnosis and detection of BMs was 13.6 (7.3-52.8) months. Moreover, we observed a significant association between BMs and bone metastases (particularly vertebral lesions). Discussion: Despite the retrospective design, this is the first study evaluating the incidence of BMs among patients with BTC in Western countries. BMs from BTC remain atypical, although their incidence is probably a little higher than previously assumed. Patients with BMs had poor prognosis. Unpredictably, bone involvement occurred in 5 out of 6 patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.
- Author
-
Garajová, Ingrid, Ferracin, Manuela, Porcellini, Elisa, Palloni, Andrea, Abbati, Francesca, Biasco, Guido, and Brandi, Giovanni
- Subjects
- *
COLON cancer , *COLON cancer treatment , *NON-coding RNA , *MICRORNA , *RIBONUCLEASES , *CANCER chemotherapy - Abstract
The onset and selection of resistant clones during cancer treatment with chemotherapy or targeted therapy is a major issue in the clinical management of metastatic colorectal cancer patients. It is possible that a more personalized treatment selection, using reliable response-to-therapy predictive biomarkers, could lead to an improvement in the success rate of the proposed therapies. Although the process of biomarker selection and validation could be a long one, requiring solid statistics, large cohorts and multicentric validations, non-coding RNAs (ncRNAs) and in particular microRNAs, proved to be extremely promising in this field. Here we summarize some of the main studies correlating specific ncRNAs with sensitivity/resistance to chemotherapy, anti-VEGF therapy, anti-EGFR therapy and immunotherapy in colorectal cancer (CRC). [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST).
- Author
-
Nannini, Margherita, Urbini, Milena, Astolfi, Annalisa, Biasco, Guido, Pantaleo, Mara A., and Pantaleo, Maria A
- Subjects
- *
GASTROINTESTINAL stromal tumors , *GENETIC mutation , *RENIN-angiotensin system , *FRAGMENTATION reactions , *DNA fingerprinting - Abstract
Recent advances in molecular biology have revolutionized the concept of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumors (GIST) than the past. Indeed, from being defined as GIST without KIT or PDGFRA mutations, we are now faced with the opposite scenario, where KIT/PDGFRA WT GIST are "positively" defined according to their specific molecular alterations. In particular, if until recently KIT/PDGFRA GIST without abnormalities of KIT, PDGFRA, SDH, and the RAS signaling pathway were referred as quadruple WT GIST, today also this small subset of GIST is emerging out as a group of heterogeneous distinct entities with multiple different molecular alterations. Therefore, given this still growing and rapidly evolving scenario, the progressive molecular fragmentation may inevitably lead over the time to the disappearance of KIT/PDGFRA WT GIST, destined to be singularly defined by their molecular fingerprint. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.
- Author
-
Ravegnini, Gloria, Sammarini, Giulia, Nannini, Margherita, Pantaleo, Maria A., Biasco, Guido, Hrelia, Patrizia, and Angelini, Sabrina
- Published
- 2017
- Full Text
- View/download PDF
28. Microbiota, NASH, HCC and the potential role of probiotics.
- Author
-
Brandi, Giovanni, De Lorenzo, Stefania, Candela, Marco, Pantaleo, Maria Abbondanza, Bellentani, Stefano, Tovoli, Francesco, Saccoccio, Gioconda, and Biasco, Guido
- Subjects
- *
PROBIOTICS , *MICROORGANISMS , *LIVER cancer , *FATTY liver , *CARCINOGENESIS - Abstract
Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. Clearly identifiable risk factors are lacking in up to 30% of HCC patients and most of these cases are attributed to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Beyond the known risk factors for NAFLD, the intestinal microbiota, in particular dysbiosis (defined as any change in the composition of the microbiota commonly found in healthy conditions) is emerging as a new factor promoting the development of chronic liver diseases and HCC. Intestinal microbes produce a large array of bioactive molecules from mainly dietary compounds, establishing an intense microbiota-host transgenomic metabolism with a major impact on physiological and pathological conditions. A better knowledge of these 'new' pathways could help unravel the pathogenesis of HCC in NAFLD to devise new prevention strategies. Currently unsettled issues include the relative role of a 'negative microbiota' (in addition to the other known risk factors for NASH) and the putative prevention of NAFLD through modulation of the gut microbiota. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Palliative medicine in Mediterranean countries: different approaches, same philosophy.
- Author
-
Pallotti, Maria Caterina, Noguera-Tejedor, Antonio, Yohan Rhee, John, Moroni, Matteo, Biasco, Guido, and Centeno, Carlos
- Published
- 2018
- Full Text
- View/download PDF
30. Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses.
- Author
-
DI MARCO, MARIA CRISTINA, GRASSI, ELISA, VECCHIARELLI, SILVIA, DURANTE, SANDRA, MACCHINI, MARINA, and BIASCO, GUIDO
- Subjects
- *
RETROPERITONEUM , *ABDOMINAL pain , *HISTOLOGY , *COMPUTED tomography , *TUMORS - Abstract
Cystic lymphangioma is a type of benign tumor originating from the lymph vessels. The tumor commonly occurs in childhood, in the head or neck regions, and retroperitoneal localization and presentations in adulthood are rare. Determining a pre-operative diagnosis is often challenging, and in the majority of cases, a diagnosis is only possible subsequent to the histological examination of the surgical specimen. A radical resection is the recommended treatment for cystic lymphangioma, and recurrence is usually due to an incomplete excision of the mass. The present study reports 2 cases of cystic lymphangioma, localized in the pancreatic gland and duodenal wall respectively, which were treated with surgical resection. The study also briefly reviews the literature regarding the differential diagnosis of retroperitoneal cystic masses. retroperitoneal or mesenteric sites, and pancreatic local- ization is rare. They are usually symptomatic and found accidentally (2). In symptomatic cases, the clinical presentation includes abdominal pain and distension. Symptoms may rarely be associated with complications, including intracystic bleeding, infection, cyst rupture or compression of adjacent organs (3). Diagnostic techniques include computed tomography (CT), magnetic resonance imaging (MRI) and endoscopic ultrasound with cyst fluid fine-needle aspiration, however, a definitive diagnosis of cystic lymphangioma is typically achieved by histological examination subsequent to surgery or exploratory laparotomy (3). Radical surgery is the recommended treatment for abdominal lymphangiomas, therefore, recurrence is rare and usually occurs due to an incomplete resection. Conservative methods, including aspi- ration, cyst enterostomy and peritoneal marsupialization, are now obsolete due to the high rate of recurrence (2). The present study reports 2 cases of retroperitoneal cystic lymphangioma that were treated by radical surgical resection and briefly reviews the literature regarding the differential diagnoses of retroperitoneal cystic masses. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma--a step towards personalized therapy.
- Author
-
Garajová, Ingrid, Funel, Niccola, Fiorentino, Michelangelo, Agostini, Valentina, Ferracin, Manuela, Negrini, Massimo, Frassineti, Giovanni Luca, Gavelli, Giampaolo, Frampton, Adam Enver, Biasco, Guido, and Giovannetti, Elisa
- Subjects
- *
MICRORNA , *ADENOCARCINOMA , *INDIVIDUALIZED medicine - Abstract
Background: Primary pulmonary enteric adenocarcinoma (PEAC) is defined as a pulmonary adenocarcinoma with a predominant component of intestinal differentiation and tumor cells positive for at least one intestinal marker. The aim of the present study was the molecular and histological characterization of a PEAC from a patient with two other family members affected by similar lung tumors, which has never been reported before. Findings: We evaluated the molecular characteristics of the proband's PEAC by using a previously validated 47-microRNA (miRNA) cancer-specific array and a predictive method to estimate tissue-of-origin probabilities. Immunohistochemical (IHC) staining for thyroid transcription factor (TTF-1), napsin A, caudal-related homeobox 2 (CDX2), cytokeratins, and mucins, as well as mutational analyses for epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), and anaplastic lymphoma kinase (ALK) were performed on formalinfixed, paraffin-embedded (FFPE) tissues. The occurrence of PEAC in two family members was associated with similar clinicopathological features (age at diagnosis, smoking habit, tumor localization, multiple colonic polyps), histologic findings (TTF-1 negativity and CDX2 positivity), and genetic findings (KRAS (Gly12Asp) mutation, but no EGFR/ALK aberrations). miRNA profiling revealed similarities with non-small cell lung cancer (NSCLC; 75.98%) and some overlap with pancreatic ductal adenocarcinoma (PDAC; 23.34%), but not with colorectal cancer (CRC; less than 0.5%). Notably, these PEACs share key PDAC-associated miRNAs associated with tumor aggressiveness (miR-31*/-126*/-506/-508-3p/-514). Conclusions: We describe for the first time PEAC in members from the same family, associated with similar clinical and genetic features. miRNA profiling of the PEAC resembled a NSCLC signature, with partial overlap to a PDAC pattern. This could explain its aggressive behavior and therefore help to guide future tailored-therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
- Author
-
Astolfi, Annalisa, Urbini, Milena, Indio, Valentina, Nannini, Margherita, Giusy Genovese, Chiara, Santini, Donatella, Saponara, Maristella, Mandrioli, Anna, Ercolani, Giorgio, Brandi, Giovanni, Biasco, Guido, and Pantaleo, Maria A.
- Subjects
- *
MUCINOUS adenocarcinoma , *FORMALDEHYDE , *GASTROINTESTINAL stromal tumors , *CYSTS (Pathology) , *NUCLEOTIDE sequencing , *GENETICS - Abstract
Background: Next generation sequencing (NGS) technology has been rapidly introduced into basic and translational research in oncology, but the reduced availability of fresh frozen (FF) tumor tissues and the poor quality of DNA extracted from formalin-fixed, paraffin-embedded (FFPE) has significantly impaired this process in the field of solid tumors. To evaluate if data generated from FFPE material can be reliably produced and potentially used in routine clinical settings, we performed whole exome sequencing (WES) from tumor samples of Gastrointestinal stromal tumors (GIST), either extracted FF or FFPE, and from matched normal DNA. Methods: We performed whole exome enrichment and sequencing at 100bp in paired end on four GIST samples, either from FFPE or fresh-frozen tissue, and from matched normal DNA. Results: The integrity of DNA extracted from FFPE was evaluated by a modified RAPD PCR method, thus identifying high quality (HQ) and low quality (LQ) FFPE. DNA library production and exome capture was feasible for both classes of FFPE, despite the smaller yield and insert size of LQ-FFPE. WES produced data of equal quality from FF and FFPE, while only HQ-FFPE yielded an amount of data comparable to FF samples. Bioinformatic analysis showed that the percentage of variants called both in FF and FFPE samples was very high in HQ-FFPE, reaching 94-96 % of the total number of called variants. Classification of somatic variants by nucleotide substitution type showed that HQ-FFPE and FF had similar mutational profiles, while LQ-FFPE samples carried a much higher number of mutations than the FF counterpart, with a significant enrichment of C > T/G > A substitutions. Focusing on potential disease-related variants allowed the discovery of additional somatic variants in GIST samples, apart from the known oncogenic driver mutation, both from sequencing of FF and FFPE material. False positive and false negative calls were present almost exclusively in the analysis of FFPE of low quality. On the whole this study showed that WES is feasible also on FFPE specimens and that it is possible to easily select FFPE samples of high quality that yield sequencing results comparable to the FF counterpart. Conclusions: WES on FFPE material may represent an important and innovative source for GIST research and for other solid tumors, amenable of possible application in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array.
- Author
-
DI MARCO, MARIACRISTINA, ASTOLFI, ANNALISA, GRASSI, ELISA, VECCHIARELLI, SILVIA, MACCHINI, MARINA, INDIO, VALENTINA, CASADEI, RICCARDO, RICCI, CLAUDIO, D'AMBRA, MARIELDA, TAFFURELLI, GIOVANNI, SERRA, CARLA, ERCOLANI, GIORGIO, SANTINI, DONATELLA, D'ERRICO, ANTONIA, PINNA, ANTONIO DANIELE, MINNI, FRANCESCO, DURANTE, SANDRA, MARTELLA, LAURA RAFFAELLA, and BIASCO, GUIDO
- Subjects
- *
PANCREATIC cancer genetics , *DUCTAL carcinoma , *RNA sequencing , *ADENOCARCINOMA , *SINGLE nucleotide polymorphisms , *GENE fusion , *GENETICS - Abstract
The aim of the current study was to implement whole transcriptome massively parallel sequencing (RNASeq) and copy number analysis to investigate the molecular biology of pancreatic ductal adenocarcinoma (PDAC). Samples from 16 patients with PDAC were collected by ultrasound-guided biopsy or from surgical specimens for DNA and RNA extraction. All samples were analyzed by RNASeq performed at 75x2 base pairs on a HiScanSQ Illumina platform. Single-nucleotide variants (SNVs) were detected with SNVMix and filtered on dbSNP, 1000 Genomes and Cosmic. Non-synonymous SNVs were analyzed with SNPs&GO and PROVEAN. A total of 13 samples were analyzed by high resolution copy number analysis on an Affymetrix SNP array 6.0. RNAseq resulted in an average of 264 coding non-synonymous novel SNVs (ranging from 146-374) and 16 novel insertions or deletions (In/Dels) (ranging from 6-24) for each sample, of which a mean of 11.2% were disease-associated and somatic events, while 34.7% were frameshift somatic In/Dels. From this analysis, alterations in the known oncogenes associated with PDAC were observed, including Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (93.7%) and inactivation of cyclin-dependent kinase inhibitor 2A (CDKN2A) (50%), mothers against decapentaplegic homolog 4 (SMAD4) (50%), and tumor protein 53 (TP53) (56%). One case that was negative for KRAS exhibited a G13D neuroblastoma RAS viral oncogene homolog mutation. In addition, gene fusions were detected in 10 samples for a total of 23 different intra- or inter-chromosomal rearrangements, however, a recurrent fusion transcript remains to be identified. SNP arrays identified macroscopic and cryptic cytogenetic alterations in 85% of patients. Gains were observed in the chromosome arms 6p, 12p, 18q and 19q which contain KRAS, GATA binding protein 6, protein kinase B and cyclin D3. Deletions were identified on chromosome arms 1p, 9p, 6p, 18q, 10q, 15q, 17p, 21q and 19q which involve TP53, CDKN2A/B, SMAD4, runt-related transcription factor 2, AT-rich interactive domain-containing protein 1A, phosphatase and tensin homolog and serine/threonine kinase 11. In conclusion, genetic alterations in PDCA were observed to involve numerous pathways including cell migration, transforming growth factor-β signaling, apoptosis, cell proliferation and DNA damage repair. However, signaling alterations were not observed in all tumors and key mutations appeared to differ between PDAC cases. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. SDHC methylation in gastrointestinal stromal tumors (GIST): a case report.
- Author
-
Urbini, Milena, Astolfi, Annalisa, Indio, Valentina, Heinrich, Michael C., Corless, Christopher L., Nannini, Margherita, Ravegnini, Gloria, Biasco, Guido, and Pantaleo, Maria A.
- Subjects
- *
DNA methylation , *SUCCINATE dehydrogenase , *GASTROINTESTINAL stromal tumors , *GENETIC mutation , *GENE expression , *GENETICS - Abstract
Background: Gastrointestinal stromal tumors (GIST) recently have been recognized as a genetically and biologically heterogeneous disease. In addition to KIT or PDGFRA mutated GIST, mutational inactivation of succinate dehydrogenase (SDH) subunits has been detected in the KIT/PDGFRA wild-type subgroup, referred to as SDH deficient (dSDH). Even though most dSDH GIST harbor mutations in SDHx subunit genes, some are SDHx wild type. Epigenetic regulation by DNA methylation of CpG islands recently has been found to be an alternative mechanism underlying the lack of SDH complex in GIST. Case presentation: We report a particular case of dSDH GIST, previously analyzed with microarrays and next-generation sequencing, for which no molecular pathogenetic events have been identified. Gene expression analysis showed remarkable down-modulation of SDHC mRNA with respect to all other GIST samples, both SDHA-mutant and KIT/PDGFRA-mutant GIST. By a bisulfite methylation assay targeted to 2 SDHC CpG islands, we detected hypermethylation of the SDHC promoter. Conclusion: Herein we report an additional case of dSDH GIST without SDHx mutation but harboring hypermethylation in the SDHC promoter, thus confirming the complexity of the molecular background of this subtype of GIST. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Celiac disease: improving the diagnosis
- Author
-
Brocchi, Emilio, Tomassetti, Paola, Biasco, Guido, Corazza, Ginoroberto, Gasbarrini, Giovanni, and Corinaldesi, R.
- Published
- 2002
- Full Text
- View/download PDF
36. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.
- Author
-
Ravegnini, Gloria, Nannini, Margherita, Sammarini, Giulia, Astolfi, Annalisa, Biasco, Guido, Pantaleo, Maria A., Hrelia, Patrizia, and Angelini, Sabrina
- Subjects
- *
GASTROINTESTINAL stromal tumors , *INDIVIDUALIZED medicine , *SOMATIC cells , *PROTEIN-tyrosine kinases , *DNA , *BIOMARKERS - Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. They are characterized by gain of function mutations in KIT or PDGFRA tyrosine kinase receptors, with their consequent constitutive activation. The gold standard therapy is imatinib that offers a good and stable response for approximately 18-36 months. However, resistance is very common and it is vital to identify new biomarkers. Up until now, there have been two main approaches with focus to characterize novel targets. On the one hand, the focus is on the tumor genome, as the final clinical outcome depends mainly from the cancer specific mutations/alterations patterns. However, the germline DNA is important as well, and it is inconceivable to think the patients response to the drug is not related to it. Therefore the aim of this review is to outline the state of the art of the personalized medicine in GIST taking into account both the tumor DNA (somatic) and the patient DNA (germline). [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
37. Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma.
- Author
-
Minichillo, Santino, Pantaleo, Maria Abbondanza, Nannini, Margherita, Coccolo, Fabio, Gatto, Lidia, Biasco, Guido, and Brandi, Giovanni
- Subjects
- *
DOCETAXEL , *DRUG efficacy , *ANGIOSARCOMA , *TUMOR treatment , *RADIOTHERAPY , *CARDIOTOXICITY , *THERAPEUTICS - Abstract
Background: Primary cardiac angiosarcoma is extremely aggressive; however, it is often misdiagnosed because of its rarity. For locally advanced tumors, doxorubicin-based chemotherapy regimens are the standard of treatment, even if the gain in term of progression-free survival is limited and is no longer than 5 months. Case presentation: We report the case of a Caucasian 23-year-old man with locally advanced cardiac angiosarcoma who underwent radical surgical resection after a prolonged response to weekly docetaxel and complementary radiotherapy. Conclusion: Combined treatment with weekly docetaxel and radiotherapy may be a valid alternative for the treatment of locally advanced cardiac angiosarcoma; the combination can lead to radical surgical resections, avoiding the cumulative cardiotoxicity of antracycline-based regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
38. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.
- Author
-
Angelini, Sabrina, Ravegnini, Gloria, Nannini, Margherita, Bermejo, Justo Lorenzo, Musti, Muriel, Pantaleo, Maria A, Fumagalli, Elena, Venturoli, Nicola, Palassini, Elena, Consolini, Nicola, Casali, Paolo G, Biasco, Guido, and Hrelia, Patrizia
- Subjects
- *
FOLIC acid deficiency , *GASTROINTESTINAL stromal tumors , *GASTROINTESTINAL tumors treatment , *GENETIC polymorphisms , *DNA synthesis - Abstract
The folate metabolism pathway has a crucial role in tumorigenesis as it supports numerous critical intracellular reactions, including DNA synthesis, repair, and methylation. Despite its importance, little is known about the influence of the folate pathway on gastrointestinal stromal tumour (GIST), a rare tumour with an incidence ranging between 6 and 19.6 cases per million worldwide. The importance of folate metabolism led us to investigate the influence of polymorphisms in the genes coding folate-metabolising enzymes on GIST susceptibility, tumour characteristics and clinical outcome. We investigated a panel of 13 polymorphisms in 8 genes in 60 cases and 153 controls. The TS 6-bp deletion allele (formerly rs34489327, delTInsTTAAAG) was associated with reduced risk of GIST (OR=0.20, 95% CI 0.05-0.67, P=0.0032). Selected polymorphisms in patients stratified by age, gender, and other main molecular and clinical characteristics showed that few genotypes may show a likely correlation. We also observed a significant association between the RFC AA/AG genotype and time to progression (HR=0.107, 95% CI 0.014-0.82; P=0.032). Furthermore, we observed a tendency towards an association between the SHMT1 variant allele (TT, rs1979277) and early death (HR=4.53, 95% CI 0.77-26.58, P=0.087). Aware of the strengths and limitations of the study, these results suggest that polymorphisms may modify the risk of GIST and clinical outcome, pointing to the necessity for further investigations with information on folate plasma levels and a larger study population. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
39. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib.
- Author
-
Reichardt, Peter, Kang, Yoon‐Koo, Rutkowski, Piotr, Schuette, Jochen, Rosen, Lee S., Seddon, Beatrice, Yalcin, Suayib, Gelderblom, Hans, Williams, Charles C., Fumagalli, Elena, Biasco, Guido, Hurwitz, Herbert I., Kaiser, Pamela E., Fly, Kolette, Matczak, Ewa, Chen, Liang, Lechuga, Maria José, and Demetri, George D.
- Subjects
- *
GASTROINTESTINAL stromal tumors , *CLINICAL trials , *IMATINIB , *DRUG efficacy , *CANCER invasiveness - Abstract
BACKGROUND The objectives of this study were to provide sunitinib to patients with gastrointestinal stromal tumor (GIST) who were otherwise unable to obtain it and to collect broad safety and efficacy data from a large population of patients with advanced GIST after imatinib failure. METHODS Imatinib-resistant/intolerant patients with advanced GIST received sunitinib on an initial dosing schedule of 50 mg daily in 6-week cycles (4 weeks on treatment, 2 weeks off treatment). Tumor assessment frequency was according to local practice, and response was assessed by investigators according to Response Evaluation Criteria in Solid Tumors version 1.0. Overall survival (OS) and safety were assessed regularly. Post hoc analyses evaluated different patterns of treatment management. RESULTS At final data cutoff, 1124 patients comprised the intent-to-treat population, and 15% of these patients had a baseline Eastern Cooperative Oncology Group performance status ≥2. The median treatment duration was 7.0 months. The median time to tumor progression was 8.3 months (95% confidence interval [CI], 8.0-9.4 months), the median OS was 16.6 months (95% CI, 14.9-18.0 months), and 36% of patients were alive at the time of analysis. Patients for whom the initial dosing schedule was modified exhibited longer median OS (23.5 months) than those who were treated strictly according to the initial dosing schedule (11.1 months). The most common treatment-related grade 3 and 4 adverse events were hand-foot syndrome (11%), fatigue (9%), neutropenia (8%), hypertension (7%), and thrombocytopenia (6%). Treatment-related adverse events associated with cardiac function (eg, congestive heart failure and myocardial infarction) were reported at frequencies of ≤1% each. CONCLUSIONS This treatment-use study confirms the long-term safety and efficacy of sunitinib in a large international population of patients with advanced GIST after imatinib failure. Cancer 2015;121:1405-1413. © 2015 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
40. Clinical and demographic factors associated to the place of death in advanced cancer patients assisted at home in Italy.
- Author
-
Varani, Silvia, Dall'Olio, Filippo G, Messana, Rossana, Tanneberger, Stephan, Pannuti, Raffaella, Pannuti, Franco, and Biasco, Guido
- Subjects
- *
CANCER patients , *CAREGIVERS , *CONFIDENCE intervals , *STATISTICAL correlation , *DEATH , *DEMOGRAPHY , *FAMILIES , *HOME care services , *HOSPICE care , *HOSPITAL care , *LONGITUDINAL method , *MULTIVARIATE analysis , *NONPARAMETRIC statistics , *SCIENTIFIC observation , *PHYSICIANS , *REGRESSION analysis , *STATISTICS , *TERMINALLY ill , *RETROSPECTIVE studies , *ODDS ratio , *KRUSKAL-Wallis Test - Abstract
Introduction Studies on the end of life have shown that patients with advanced cancer prefer to die at home, and their caregivers agree with this choice. However, many cancer patients still die in hospital. Few data are available for Southern Europe and, in particular, for Italy. This study examined the factors associated with the place of death in a cohort of Italian patients with advanced cancer who were assisted by a palliative home care team. Methods We conducted a retrospective observational study to identify the association between place of death and clinical and demographic factors in a sample of 1374 patients. To analyze the factors associated with the place of death, we used univariate analyses by nonparametric tests and multinomial regression tests. Results Five variables related to the place of death were significant in univariate analysis, but only three were retained significant in the multinomial regression test. The older patients died more frequently at home rather than in hospital (P < 0.05); a greater number of home visits by a physician in the last 30 days of home care was correlated with dying at home (P < 0.001), a greater number of hospitalizations during the last 30 days of home care was correlated with dying in hospital and in hospice (P < 0.001). Conclusions The study shows that at the end of life the frequency of home visits by the palliative care physicians and a continuous at-home palliative service could favor dying at home in a cohort of cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
41. Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.
- Author
-
SAPONARA, MARISTELLA, LOLLI, CRISTIAN, NANNINI, MARGHERITA, SCIOSCIO, VALERIO DI, SERRA, CARLA, MANDRIOLI, ANNA, PALLOTTI, MARIA CATERINA, BIASCO, GUIDO, and PANTALEO, MARIA ABBONDANZA
- Subjects
- *
GASTROINTESTINAL tumors , *GASTROINTESTINAL agents , *IMATINIB , *TOXICITY testing , *DISEASE progression - Abstract
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumour of the gastrointestinal tract. The advent of targeted kinase-inhibitors has revolutionised treatment strategies and clinical outcomes for patients with advanced GIST. In the majority of countries, sunitinib is the only approved second-line treatment option for advanced GIST patients, who are resistant or intolerant to imatinib. However, sunitinib is associated with various adverse events, which often result in a reduction of the dosage, and interruption or suspension of therapy. Effective therapy management is essential to obtain the maximum clinical benefit, and includes adequate side effect management as well as optimization of dosing and treatment duration. In the current study, examples of maximization of treatment with sunitinib are presented, describing three clinical cases in which therapy with sunitinib was continued via the adoption of alternative reduced schedules or an additional loco-regional treatment, in order to manage toxicities or overcome progressive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
42. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).
- Author
-
Nannini, Margherita, Astolfi, Annalisa, Urbini, Milena, Indio, Valentina, Santini, Donatella, Heinrich, Michael C., Corless, Christopher L., Ceccarelli, Claudio, Saponara, Maristella, Mandrioli, Anna, Lolli, Cristian, Ercolani, Giorgio, Brandi, Giovanni, Biasco, Guido, and Pantaleo, Maria A.
- Subjects
- *
GASTROINTESTINAL stromal tumors , *TUMORS in children , *PLATELET-derived growth factor receptors , *SUCCINATE dehydrogenase , *NEUROFIBROMATOSIS 1 - Abstract
Background: About 10-15% of adult gastrointestinal stromal tumors (GIST) and the vast majority of pediatric GIST do not harbour KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations (J Clin Oncol 22:3813-3825, 2004; Hematol Oncol Clin North Am 23:15-34, 2009). The molecular biology of these GIST, originally defined as KIT/PDGFRA wild-type (WT), is complex due to the existence of different subgroups with distinct molecular hallmarks, including defects in the succinate dehydrogenase (SDH) complex and mutations of neurofibromatosis type 1 (NF1), BRAF, or KRAS genes (RAS-pathway or RAS-P). In this extremely heterogeneous landscape, the clinical profile and molecular abnormalities of the small subgroup of WT GIST suitably referred to as quadruple wild-type GIST (quadrupleWT or KITWT/PDGFRAWT/SDHWT/RAS-PWT) remains undefined. The aim of this study is to investigate the genomic profile of KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST, by using a massively parallel sequencing and microarray approach, and compare it with the genomic profile of other GIST subtypes. Methods: We performed a whole genome analysis using a massively parallel sequencing approach on a total of 16 GIST cases (2 KITWT/PDGFRAWT/SDHWT and SDHBIHC+/SDHAIHC+, 2 KITWT/PDGFRAWT/SDHAmut and SDHBIHC-/SDHAIHC- and 12 cases of KITmut or PDGFRAmut GIST). To confirm and extend the results, whole-genome gene expression analysis by microarray was performed on 9 out 16 patients analyzed by RNAseq and an additional 20 GIST patients (1 KITWT/PDGFRAWT SDHAmut GIST and 19 KITmut or PDGFRAmut GIST). The most impressive data were validated by quantitave PCR and Western Blot analysis. Results: We found that both cases of quadrupleWT GIST had a genomic profile profoundly different from both either KIT/PDGFRA mutated or SDHA-mutated GIST. In particular, the quadrupleWT GIST tumors are characterized by the overexpression of molecular markers (CALCRL and COL22A1) and of specific oncogenes including tyrosine and cyclin- dependent kinases (NTRK2 and CDK6) and one member of the ETS-transcription factor family (ERG). Conclusion: We report for the first time an integrated genomic picture of KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST, using massively parallel sequencing and gene expression analyses, and found that quadrupleWT GIST have an expression signature that is distinct from SDH-mutant GIST as well as GIST harbouring mutations in KIT or PDGFRA. Our findings suggest that quadrupleWT GIST represent another unique group within the family of gastrointestintal stromal tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. The ‘surprise’ question in advanced cancer patients: A prospective study among general practitioners.
- Author
-
Moroni, Matteo, Zocchi, Donato, Bolognesi, Deborah, Abernethy, Amy, Rondelli, Roberto, Savorani, Giandomenico, Salera, Marcello, Dall’Olio, Filippo G, Galli, Giulia, and Biasco, Guido
- Published
- 2014
- Full Text
- View/download PDF
44. The ‘surprise’ question in advanced cancer patients: A prospective study among general practitioners.
- Author
-
Moroni, Matteo, Zocchi, Donato, Bolognesi, Deborah, Abernethy, Amy, Rondelli, Roberto, Savorani, Giandomenico, Salera, Marcello, Dall’Olio, Filippo G, Galli, Giulia, and Biasco, Guido
- Subjects
- *
CONFIDENCE intervals , *FISHER exact test , *LONGITUDINAL method , *GENERAL practitioners , *PROBABILITY theory , *STATISTICAL sampling , *STATISTICAL hypothesis testing , *STATISTICS , *T-test (Statistics) , *TUMORS , *TUMOR classification , *DATA analysis , *PROPORTIONAL hazards models , *DATA analysis software , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator , *ODDS ratio , *PSYCHOLOGY ,TUMOR prognosis - Abstract
The article presents a study aimed to identified the prognostic accuracy by the general practitioners asking "surprise" questions about their patients. The study is conducted through a prospective cohort method on 42 of 50 randomly select general practitioners in the Bologna area of Italy between December 2011 and February 2012. The results of the study show that when general practitioners use "surprise" questions particularly for patients with cancer, the survival prognosis was high.
- Published
- 2014
- Full Text
- View/download PDF
45. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study.
- Author
-
Berruti, Alfredo, Fazio, Nicola, Ferrero, Anna, Brizzi, Maria Pia, Volante, Marco, Nobili, Elisabetta, Tozzi, Lucia, Bodei, Lisa, Torta, Mirella, D'Avolio, Antonio, Priola, Adriano Massimiliano, Birocco, Nadia, Amoroso, Vito, Biasco, Guido, Papotti, Mauro, and Dogliotti, Luigi
- Subjects
- *
NEUROENDOCRINE tumors , *BEVACIZUMAB , *DRUG side effects , *VASCULAR endothelial growth factors , *GENETIC polymorphisms , *PROTEINURIA , *TUMOR treatment - Abstract
Background: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). Ancillary studies evaluated hypertension, proteinuria, and vascular endothelial growth factor (VEGF) polymorphisms in predicting progression-free survival (PFS) and the predictive role of serum vitamin D in progression-free survival and proteinuria onset. Methods: This prospective phase 2 study included 45 patients with WMD-NEN arising from various primary sites. The treatment regimen was octreotide long-acting release (LAR), 20 mg monthly, metronomic capecitabine, 2000 mg/daily, and intravenous bevacizumab, 5 mg/kg every 2 weeks, without interruption for 9 months. Bevacizumab was continued until disease progression. Results: Partial response was obtained in 8 patients (17.8%, 95% confidence interval [CI], 6.4%-28.2%); tumor response was more frequent in pancreatic than in non-pancreatic malignancies. The median PFS was 14.9 months; median overall survival was not attained. Biochemical and symptomatic responses were observed in 52.9% and 82.3% of cases, respectively. The treatment was well tolerated. Grade 3 toxicities included hand and foot syndrome (11.1%), proteinuria (4.4%), and renal toxicity (2.2%). Proteinuria (all grades) was correlated with longer PFS (p = 0.017). There was an inverse relationship between proteinuria and vitamin D levels. VEGF polymorphisms were not associated with patient outcome. Conclusion: The XELBEVOCT regimen is active and well tolerated in patients with metastatic WMD-NEN. Proteinuria correlated with hypovitaminosis D status and was the best predictive factor of treatment efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
46. Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST.
- Author
-
Pantaleo, Maria A, Astolfi, Annalisa, Urbini, Milena, Nannini, Margherita, Paterini, Paola, Indio, Valentina, Saponara, Maristella, Formica, Serena, Ceccarelli, Claudio, Casadio, Rita, Rossi, Giulio, Bertolini, Federica, Santini, Donatella, Pirini, Maria G, Fiorentino, Michelangelo, Basso, Umberto, and Biasco, Guido
- Subjects
- *
GASTROINTESTINAL stromal tumors , *PLATELET-derived growth factor receptors , *SUCCINATE dehydrogenase , *GENETIC mutation , *NUCLEIC acid isolation methods - Abstract
Mutations of genes encoding the subunits of the succinate dehydrogenase (SDH) complex were described in KIT/PDGFRA wild-type GIST separately in different reports. In this study, we simultaneously sequenced the genome of all subunits, SDHA, SDHB, SDHC, and SDHD in a larger series of KIT/PDGFRA wild-type GIST in order to evaluate the frequency of the mutations and explore their biological role. SDHA, SDHB, SDHC, and SDHD were sequenced on the available samples obtained from 34 KIT/PDGFRA wild-type GISTs. Of these, in 10 cases, both tumor and peripheral blood (PB) were available, in 19 cases only tumor, and in 5 cases only PB. Overall, 9 of the 34 patients with KIT/PDGFRA wild-type GIST carried mutations in one of the four subunits of the SDH complex (six patients in SDHA, two in SDHB, one in SDHC). WB and immunohistochemistry analysis showed that patients with KIT/PDGFRA wild-type GIST who harbored SDHA mutations exhibited a significant downregulation of both SDHA and SDHB protein expression, with respect to the other GIST lacking SDH mutations and to KIT/PDGFRA-mutated GIST. Clinically, four out of six patients with SDHA mutations presented with metastatic disease at diagnosis with a very slow, indolent course. Patients with KIT/PDGFRA wild-type GIST may harbor germline and/or de novo mutations of SDH complex with prevalence for mutations within SDHA, which is associated with a downregulation of SDHA and SDHB protein expression. The presence of germline mutations may suggest that these patients should be followed up for the risk of development of other cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
- Author
-
Brandi, Giovanni, Rosa, Francesco, Calzà, Laura, Girolamo, Stefania Di, Tufoni, Manuel, Ricci, Carmen Serena, Cirignotta, Fabio, Caraceni, Paolo, and Biasco, Guido
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *HEPATIC encephalopathy , *LIVER cancer , *CIRRHOSIS of the liver , *COGNITION disorders - Abstract
Background Sorafenib is the standard treatment of advanced hepatocarcinoma ( HCC) in cirrhotic patients with preserved liver function. It shares many adverse effects with other tyrosine-kinase ( TK) inhibitors and antiangiogenic drugs. TK inhibitors could have a direct toxicity on CNS, both by interfering with TK-related pathways and by inhibiting angiogenesis. Aims The aim of this study was to investigate whether sorafenib administration can be associated to metabolic encephalopathy in patients with cirrhosis. Methods We retrospectively reviewed medical records of all cirrhotic patients treated with sorafenib for HCC afferent at our Department from January 2009 to December 2011. Results Among 62 patients, we identified 10 patients with clinically significant cognitive impairment. Seven of these were clearly diagnosed with overt hepatic encephalopathy ( HE), one with brain metastases and two with drug-related toxic-metabolic encephalopathy. These last two cases were characterized by severe cognitive impairment, mood alteration and memory deficit. Clinical exam, blood tests and brain CT excluded organic causes of encephalopathy and precipitating factors of HE. Sorafenib discontinuation was associated with complete reversal of the syndrome, which recurred on drug re-administration in one case. Conclusions Our study suggests that sorafenib may be a precipitating factor of metabolic encephalopathy in cirrhotic patients with advanced HCC. This neurological syndrome appears to be not responsive to the conventional treatment for HE, but it is fully reversible by drug discontinuation. It can be speculated that the potential direct neuronal action of sorafenib may represent a trigger for the onset of metabolic encephalopathy in a subset of cirrhotic patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
48. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy
- Author
-
Angelini, Sabrina, Pantaleo, Maria Abbondanza, Ravegnini, Gloria, Zenesini, Corrado, Cavrini, Giulia, Nannini, Margherita, Fumagalli, Elena, Palassini, Elena, Saponara, Maristella, Di Battista, Monica, Casali, Paolo G., Hrelia, Patrizia, Cantelli-Forti, Giorgio, and Biasco, Guido
- Subjects
- *
GENETIC polymorphisms , *ORGANIC cation transporters , *GASTROINTESTINAL stromal tumors , *IMATINIB , *PROTEIN-tyrosine kinase inhibitors , *CHRONIC myeloid leukemia , *TUMOR treatment - Abstract
Abstract: The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and imatinib, a selective tyrosine kinase inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST. Response to imatinib mainly depends from KIT and PDGFRα mutational status. Nevertheless, some patients with a potentially responsive genotype do not respond, and others develop a pattern of resistance to imatinib which is not associated with secondary mutations. This emphasizes the presence of mechanisms of resistance other than the receptor-related genotype, and the need of biological predictors to select the optimal therapeutic strategy, particularly now that other potent inhibitors are available. We investigated a panel of 31 polymorphisms in 11 genes, potentially associated with the pharmacogenetics of imatinib, in a group of 54 unresectable/metastatic GISTs treated with imatinib 400mg daily as first line therapy. Included in this analysis were polymorphisms in the transporters’ family SLC22, SLCO, ABC, and in the metabolizing genes CYP-3A4 and -3A5. Time to progression was significantly improved in presence of the C allele in SLC22A4 (OCTN1 rs1050152), and the two minor alleles (G) in SLC22A5 (OCTN2 rs2631367 and rs2631372). Importantly, multivariate analysis, adjusting for age, gender, KIT/PDGFRα mutational status, and tumour size, revealed that all the three genotypes maintained independent predictive significance. In conclusion, in this study we showed that SLC22A4 and SLC22A5 genotypes may be an important predictor of time to progression in GIST patients receiving imatinib therapy. Further investigations are required in an attempt to further personalize GIST therapy. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
49. Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases.
- Author
-
Brandi, Giovanni, Corbelli, Jody, Rosa, Francesco, Girolamo, Stefania, Longobardi, Ciro, Agostini, Valentina, Garajová, Ingrid, Rovere, Stefano, Ercolani, Giorgio, Grazi, Gian, Pinna, Antonio, and Biasco, Guido
- Subjects
- *
COLON cancer , *CANCER chemotherapy , *SURGICAL excision , *METASTASIS , *COMBINED modality therapy - Abstract
Purpose: Limited data suggest that second resections for colorectal cancer metastases may improve survival, but no study has compared surgery with chemotherapy in this setting. Therefore, we retrospectively compared the clinical outcome of potentially resectable patients who received a second metastasectomy with those who did not in our single-centre experience. Methods: We retrospectively reviewed the clinical records of all patients treated for metastatic colorectal cancer in our centre over a period of 12 years. We selected patients who relapsed after radical resection of metastases from colorectal cancer and were deemed resectable again by our multidisciplinary team. We then compared the clinical outcome of those who received a second operation with those who refused surgery and also evaluated the role of prognostic factors. Results: We identified 60 patients fulfilling the inclusion criteria. Twenty-nine underwent a second resection and 31 refused surgery. Median overall survival rates were 58.7 and 24.0 months, median times to progression were 14.4 and 6.6 months. Patients who received surgery plus perioperatory chemotherapy (18/29) had a significantly better outcome; 4/29 achieved long-term disease-free survival. Conclusions: Our study suggests that in highly selected metastatic colorectal cancer patients, a multimodal treatment plan, including a second resection, can achieve longer survival with respect to medical therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
50. Using Sociodrama and Psychodrama To Teach Communication in End-of-Life Care.
- Author
-
Baile, Walter F., De Panfilis, Ludovica, Tanzi, Silvia, Moroni, Matteo, Walters, Rebecca, and Biasco, Guido
- Subjects
- *
DRAMA therapy , *ATTITUDE (Psychology) , *COMMUNICATION , *CURRICULUM , *EMOTIONS , *PALLIATIVE treatment , *ROLE playing , *VALUES (Ethics) , *ADULT education workshops , *GROUP process , *TEACHING methods , *COURSE evaluation (Education) , *MASTERS programs (Higher education) - Abstract
End-of-life discussions can be stressful and can elicit strong emotions in the provider as well as the patient and family. In palliative care, understanding and effectively addressing emotions is a key skill that can enhance professional competency and patient/family satisfaction with care. We illustrate how in coursework for a Master's degree in palliative medicine we used dramatic 'action methods' derived from sociodrama and psychodrama in the portrayal of two challenging cases to train providers in the emotional aspects of caring for patients with advanced cancer. We describe the specific techniques of constructing and enacting case scenarios using warm-ups, role-creation, doubling and role-reversal. In particular, we illustrate how these techniques and others were used to reveal and address the 'hidden' emotions, attitudes, and values that were central to the communication dilemma. Finally, we present an evaluation completed by the 26 participants who attended the course. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.